Familiarizing yourself with the availability of Novo Nordisk’s Retatrutide and this joint supplement is presently important for individuals potential relief for metabolic conditions and osteoarthritis respectively. This dual GLP-1/GIP receptor agonist is currently lacking widespread authorization in various regions , with select clinical trials